EMA Focuses on Greater International Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Focuses on Greater International Collaboration


Pharmaceutical Technology Europe


References

1. EMA website, "Partners & Networks," http://www.ema.europa.eu/, accessed 7 Sept. 2012.

2. EMA website, "Road Map to 2015," http://www.ema.europa.eu/, accessed 7 Sept. 2012.

3. K. Tadano, "PMDA's International Strategic Plan and its Implementation" (PMDA website), http://www.pharm.kitasato-u.ac.jp/, accessed 7 Sept. 2012.

4. Centre for Innovation in Regulatory Science (CIRS) website, "May 2012 Slide of the Month," http://cirsci.org/, accessed 7 Sept. 2012.

5. EMA website, "Report on interactions between the Japanese Ministry of Health, Labour and Welfare (MHLW)/Pharmaceuticals and Medical Devices Agency (PMDA) and the European Medicines Agency (EMA)," http://www.ema.europa.eu/, accessed 7 Sept. 2012.

6. Y. Hayashi, "EU, USA and Japan (II)– Reports from Regulators on Exchange Assignments" (PMDA website), http://www.pmda.go.jp/, accessed 7 Sept. 2012.

7. EMA website, "European Union — Japan orphan medicines cooperation". http://www.ema.europa.eu/, accessed 7 Sept. 2012.

8. EC website, "Medicines Regulation: Transatlantic Administrative Simplification Action Plan," http://ec.europa.eu/, accessed 7 Sept. 2012.

9. EMA website, "Enhancing GMP Inspection Cooperation Between the EMA and FDA," http://www.ema.europa.eu/, accessed 10 Sept. 2012.

10. WHO website, "Essential medicines for children". http://www.who.int/, accessed 7 Sept. 2012.

11. E. Silverman, "Clinical Trial Deaths In India Dropped" (Pharmalot website, 2012), http://www.pharmalot.com/, accessed 7 Sept. 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology Europe,
Click here